AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Akari Therapeutics, Plc

24 West 40th Street
8th Floor
New York, NY 10018
United States

Sector : Healthcare
Industry : Biotechnology
Full Time Employees : 13

Key Executives

Name Title Pay Exercised Year Born
Dr. Ray Prudo Exec. Chairman 318.27k N/A 1945
Mr. Clive Richardson COO, Director & Interim CEO 520.84k N/A 1965
Mr. Dov Elefant Chief Financial Officer 343.69k N/A 1967
Dr. Miles Nunn Chief Scientific Officer N/A N/A N/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.

Corporate Governance

Akari Therapeutics, Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) . Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.